Implementing HoLEP in an Academic Department With Multiple Surgeons in Training: Mentoring Is the Key for Success
Abstract
Objective Holmium laser enucleation of the prostate (HoLEP) has been recommended for the surgical management
of benign prostatic hyperplasia (BPH) in most of the international guidelines, regardless of prostatic volume. The
main advantages reported by randomized clinical studies are reduced perioperative bleeding, catheterization time,
and length of hospital stay, but this technique is also described as difficult to master with a steep learning curve.
The objective of this study was to describe the clinical outcomes of HoLEP in the real-life setting of an academic
department with multiple operators with no previous experience.
Methods A retrospective observational study was conducted including all consecutive cases performed in our
department from April 2012 to October 2020. Over the study period, 31 different operators were involved. In April
2012, 2 surgeons were trained by an experienced urologist. The 29 others learned the technique progressively with the
help of the first 2 surgeons (surgical mentoring).
Results A total of 1259 patients were included. Preoperatively, the mean prostate volume and Qmax were 82.3 g
and 9.4 mL/s, respectively. The mean operative time was 79.7 min. The intraoperative complication rate was 5.6%
(n = 71), with the need for conversion being 0.6%. Postoperatively, the complication rate was 18.6% (n = 234). Surgeon’s
experience reduced the perioperative complication rates (P = 0.01), operative time (P < 0.001), and length of hospital
stay (P < 0.001), but the difference in blood transfusion rate was statistically non-significant (P = 0.3).
Conclusions Most of the 31 urologists in training were able to master HoLEP progressively, with good functional
outcomes and acceptable complication rates. Supervision by trained urologists was critical for the safe dissemination
of the technique in our department.
The Société International d'Urologie (SIU), which owns and publishes the Société International d'Urologie Journal (SIUJ), does not require authors of papers published in the journal to transfer copyright. Instead, we ask authors to grant an exclusive licence that allows us to publish the article in SIUJ (and any derivative or related products or publications) and that allows us to sub-license such rights and exploit all subsidiary rights.
Authors retain the right to use their own articles for their own non-commercial purposes without seeking explicit permission from SIU.
The SIUJ publication licence expressly defines “non-commercial” as “not primarily intended for or directed towards commercial advantage or monetary compensation.” Although no activity is completely disconnected from commercial activity, the following are generally considered to be non-commercial uses:
- Reproduction of a reasonable number (no more than 100) of print copies of the published paper for personal use (e.g., sharing with colleagues, including in grant applications).
- Posting a copy of the published version of the paper on the author’s own or their institution’s website. The article must be accompanied by this statement: ‘This article has been published in the SIUJ: [full citation; link]’.
- Inclusion of the paper in a course pack, with a maximum of 100 copies to be used in the author’s institution. The copies must include the following acknowledgement: ‘This article has been published in the SIUJ: [full citation; link].’
As the distinction between commercial and non-commercial is not always clear, authors are strongly advised to seek permission from SIU for any use that may be considered to have a commercial aspect.
We ask the corresponding author to read the terms of the licence and then to grant this exclusive licence on behalf of all authors by indicating agreement to the following statement:
The corresponding author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence on a worldwide basis to the SIU and its licensees to permit this article (if accepted) to be published in the SIUJ and any other SIU products and publications and to exploit all subsidiary rights, as set out in our licence agreement.
Review and Decision
Most submissions will be reviewed by a senior editor within 2 weeks. Many manuscripts will be rejected at this point for a variety of reasons, including subject matter outside the scope of the SIUJ, flawed design, discredited or outdated methodology, poor organization or presentation, failure to conform to ethical requirements, and apparent plagiarism.The remaining manuscripts will be sent for peer review. The SIUJ uses a single-blind process: reviewers know the identity of the authors, but the authors are not told who has reviewed their manuscript, and SIUJ ensures that potentially identifying information is removed from comments sent to them. Reviewers are asked to make their recommendations within 10 days, after which a senior/specialist editor will consider their comments and recommend provisional acceptance dependent on satisfactory revision, acceptance without revision, or rejection. Authors should receive a final decision within 4 to 6 weeks of submission.
